Head-To-Head Review: Lisata Therapeutics (NASDAQ:LSTA) versus Vera Therapeutics (NASDAQ:VERA)

Vera Therapeutics (NASDAQ:VERA) and Lisata Therapeutics (NASDAQ:LSTA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Vera Therapeutics and Lisata Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1	1	10	0	2.75
Lisata Therapeutics	1	1	1	0	2.00

Vera Therapeutics currently has a consensus price target of $81.45, suggesting a potential upside of 109.61%. Lisata Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 198.80%. Given Lisata Therapeutics’ higher possible upside, analysts clearly believe Lisata Therapeutics is more favorable than Vera Therapeutics.

Volatility and Risk

Vera Therapeutics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500.

Institutional and Insider Ownership

99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 16.3% of Vera Therapeutics shares are owned by insiders. Comparatively, 9.6% of Lisata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Vera Therapeutics and Lisata Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-59.72%	-49.10%
Lisata Therapeutics	N/A	-85.50%	-70.85%

Valuation and Earnings

This table compares Vera Therapeutics and Lisata Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61 million	($4.66)	-8.34
Lisata Therapeutics	$170,000.00	266.65	-$16.59 million	($1.91)	-2.63

Lisata Therapeutics has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

About Vera Therapeutics

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

About Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.